By

Luke Timmerman

20
Apr
2023

The Supreme Court and the FDA

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
12
Apr
2023

The Frontier of Epigenetic Editing: Chroma CEO Catherine Stehman-Breen

Today’s guest on The Long Run is Catherine Stehman-Breen. Catherine is the CEO of Boston-based Chroma Medicine. Chroma is working on therapies that control gene expression through epigenetic editing. People have heard a lot about editing of the genome with CRISPR, and then subsequent refinements of the technology known as base editing and prime editing. The question at Chroma is...
Read More
29
Mar
2023

Timmerman Traverse for Life Science Cares is Back

The next biotech team adventure is here. I’m thrilled to announce the Timmerman Traverse for Life Science Cares 2023. We’re on a mission to raise $1 million. We’re giving it all back to the most vulnerable people in the communities where we live and work. This trip involves shared sacrifice. We will cover 20+ miles and gain 8,000 feet of...
Read More
14
Mar
2023

The Future of Neuroscience Drug R&D: Ryan Watts on The Long Run

Today’s guest on The Long Run is Ryan Watts. Ryan is the co-founder and CEO of South San Francisco-based Denali Therapeutics. Denali is one of the prominent development-stage biotech companies working on treatments for neurodegenerative diseases. It has a pipeline with seven drug candidates in clinical development. It’s developing small molecules and large molecules against a range of neurodegenerative diseases...
Read More